LWB1
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more
LWB1 (LWB1) - Total Liabilities
Latest total liabilities as of June 2025: €187.24 Million EUR
Based on the latest financial reports, LWB1 (LWB1) has total liabilities worth €187.24 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LWB1 - Total Liabilities Trend (2022–2025)
This chart illustrates how LWB1's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
LWB1 Competitors by Total Liabilities
The table below lists competitors of LWB1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SES S.A
PINK:SGBAF
|
USA | $7.65 Billion |
|
KPJ Healthcare Bhd
KLSE:5878
|
Malaysia | RM4.90 Billion |
|
SUZHOU KEMATEK INC
SHE:301611
|
Brazil | CN¥736.34 Million |
|
City Union Bank Limited
NSE:CUB
|
India | ₹744.76 Billion |
|
Nantong Jianghai Capacitor Co Ltd
SHE:002484
|
China | CN¥2.57 Billion |
|
Trust Alliance Information Development Inc Ltd Shanghai
SHE:300469
|
China | CN¥705.49 Million |
|
Wacoal Holdings Corp
PINK:WACLY
|
USA | $77.29 Billion |
|
Doosan Bobcat Inc
KO:241560
|
Korea | ₩5.18 Trillion |
Liability Composition Analysis (2022–2025)
This chart breaks down LWB1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LWB1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LWB1 (2022–2025)
The table below shows the annual total liabilities of LWB1 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | €187.24 Million | -0.82% |
| 2024-06-30 | €188.80 Million | +12.66% |
| 2023-06-30 | €167.58 Million | +1.50% |
| 2022-06-30 | €165.10 Million | -- |